$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc

$qprc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025520 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$202.5K	$54.19K	$451.2K
YoY Change	65.98%	-97.36%	-77.99%
Cost Of Revenue			$85.00K
YoY Change
Gross Profit	$14.53K		$147.5K
YoY Change	22.13%		-79.93%
Gross Profit Margin	7.17%		32.7%
Selling, General & Admin	$777.9K	$219.7K	$1.980M
YoY Change	42.04%	-40.01%	-48.56%
% of Gross Profit	5354.56%		1341.97%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$158.9K	$198.5K	$910.3K
YoY Change	-48.46%	36.81%	-21.51%
% of Gross Profit	1093.62%		617.08%
Operating Expenses	$777.9K	$417.7K	$1.980M
YoY Change	42.04%	14.06%	-48.56%
Operating Profit	-$763.3K		-$1.832M
YoY Change	42.48%		-41.15%
Interest Expense	-$146.0K	-$59.02K	$82.72K
YoY Change	-137.83%	-126.43%	-110.7%
% of Operating Profit
Other Income/Expense, Net	-$146.0K	$0.00	$1.077M
YoY Change		-100.0%	88.67%
Pretax Income	-$909.4K	-$488.7K	-$754.8K
YoY Change	507.21%	-159.38%	-81.83%
Income Tax	$30.00K	-$14.14K	-$1.253K
% Of Pretax Income
Net Earnings	-$939.4K	-$474.6K	-$753.5K
YoY Change	477.57%	-157.67%	-81.86%
Net Earnings / Revenue	-463.88%	-875.81%	-167.0%
Basic Earnings Per Share	-$0.17		-$0.14
Diluted Earnings Per Share	-$0.17	-$0.09	-$0.14
COMMON SHARES
Basic Shares Outstanding	5.332M shares	5.333M shares	5.332M shares
Diluted Shares Outstanding	5.332M shares		5.333M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.9K	$90.60K	$90.60K
YoY Change	-50.17%	-65.79%	-65.79%
Cash & Equivalents	$126.9K	$90.60K	$90.60K
Short-Term Investments
Other Short-Term Assets	$17.92K	$5.321K	$5.320K
YoY Change	-32.86%	-56.76%	-56.78%
Inventory
Prepaid Expenses		$5.321K
Receivables
Other Receivables
Total Short-Term Assets	$144.8K	$95.92K	$95.92K
YoY Change	-51.2%	-65.39%	-65.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$4.272M	$1.131M
YoY Change		109.67%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.272M	$1.131M	$1.131M
YoY Change	230.86%	109.67%	109.68%
TOTAL ASSETS
Total Short-Term Assets	$144.8K	$95.92K	$95.92K
Total Long-Term Assets	$4.272M	$1.131M	$1.131M
Total Assets	$4.417M	$1.227M	$1.227M
YoY Change	178.15%	50.26%	50.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$171.4K	$148.5K	$148.5K
YoY Change	16.27%	14.76%	14.76%
Accrued Expenses	$1.040M	$904.6K	$904.6K
YoY Change	80.04%	83.87%	83.87%
Deferred Revenue
YoY Change
Short-Term Debt	$9.535M	$5.591M	$5.591M
YoY Change	107.26%	-9.02%	67.36%
Long-Term Debt Due	$2.797M	$2.797M	$2.797M
YoY Change	-0.33%	-0.3%	-0.3%
Total Short-Term Liabilities	$13.70M	$9.586M	$9.586M
YoY Change	47.34%	14.08%	14.08%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	0.54%	0.0%	0.0%
Other Long-Term Liabilities	$53.67K	$53.67K	$53.67K
YoY Change	-71.75%	-71.75%	-71.75%
Total Long-Term Liabilities	$203.7K	$203.7K	$203.7K
YoY Change	-39.95%	-40.1%	-40.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.70M	$9.586M	$9.586M
Total Long-Term Liabilities	$203.7K	$203.7K	$203.7K
Total Liabilities	$13.90M	$9.790M	$9.790M
YoY Change	44.27%	11.97%	11.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.13M	-$26.19M
YoY Change		2.96%
Common Stock	$160.00	$160.00
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.484M	-$8.563M	-$8.563M
YoY Change
Total Liabilities & Shareholders Equity	$4.417M	$1.227M	$1.227M
YoY Change	178.15%	50.26%	50.26%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$939.4K	-$474.6K	-$753.5K
YoY Change	477.57%	-157.67%	-81.86%
Depreciation, Depletion And Amortization	$158.9K	$198.5K	$910.3K
YoY Change	-48.46%	36.81%	-21.51%
Cash From Operating Activities	-$607.8K	-$150.2K	-$914.2K
YoY Change	189.21%	-122.75%	1740.5%
INVESTING ACTIVITIES
Capital Expenditures	$3.300M	$0.00	$1.502M
YoY Change	-411.32%	-100.0%	-230.61%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.300M	$0.00	-$1.502M
YoY Change	211.32%	-100.0%	30.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.944M	164.8K	$2.242M
YoY Change	213.03%	-377.51%	84.27%
NET CHANGE
Cash From Operating Activities	-$607.8K	-150.2K	-$914.2K
Cash From Investing Activities	-$3.300M	0.000	-$1.502M
Cash From Financing Activities	$3.944M	164.8K	$2.242M
Net Change In Cash	$36.31K	14.63K	-$174.2K
YoY Change	-456.98%	-71.29%	-1126.14%
FREE CASH FLOW
Cash From Operating Activities	-$607.8K	-$150.2K	-$914.2K
Capital Expenditures	$3.300M	$0.00	$1.502M
Free Cash Flow	-$3.908M	-$150.2K	-$2.416M
YoY Change	-559.84%	-112.41%	-319.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	33-18099-NY
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2873662
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	411 Theodore Fremd Ave
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 206S
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rye
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10580-1411
CY2022	dei	City Area Code CityAreaCode	(888)
CY2022	dei	Local Phone Number LocalPhoneNumber	743-7577
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	4266678	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5331973	shares
CY2022	dei	Auditor Firm AuditorFirmId	89
CY2022	dei	Auditor Name AuditorName	Rosenberg Rich Baker Berman, P.A.
CY2022	dei	Auditor Location AuditorLocation	Somerset, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90601	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	264840	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5321	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12305	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	95922	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	277145	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1625846	usd
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	715519	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1131154	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	539481	usd
CY2022Q4	us-gaap	Assets Assets	1227076	usd
CY2021Q4	us-gaap	Assets Assets	816626	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	148533	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	129426	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2022Q4	qprc	Funding Liability FundingLiability	5453204	usd
CY2021Q4	qprc	Funding Liability FundingLiability	3202765	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2796500	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2805000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	145428	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1636187	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	904573	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	491971	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9586238	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8403349	usd
CY2022Q4	qprc	Loans Payable Sba LoansPayableSba	150000	usd
CY2021Q4	qprc	Loans Payable Sba LoansPayableSba	150000	usd
CY2022Q4	qprc	Purchase Price Of Patents PurchasePriceOfPatents	53665	usd
CY2021Q4	qprc	Purchase Price Of Patents PurchasePriceOfPatents	190000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9789903	usd
CY2021Q4	us-gaap	Liabilities Liabilities	8743349	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00003
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00003
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5331973	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5331973	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5333347	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5333347	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17626279	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17508867	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26189494	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25435978	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8563055	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7926951	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8562827	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7926723	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1227076	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	816626	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	451194	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2050000	usd
CY2022	qprc	Litigation And Licensing Expenses LitigationAndLicensingExpenses	303671	usd
CY2021	qprc	Litigation And Licensing Expenses LitigationAndLicensingExpenses	1314928	usd
CY2022	us-gaap	Gross Profit GrossProfit	147523	usd
CY2021	us-gaap	Gross Profit GrossProfit	735072	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1979718	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3848611	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1979718	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3848611	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1832195	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3113539	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	1850018	usd
CY2021	us-gaap	Other Income OtherIncome	1725965	usd
CY2021	qprc	Warrant Expenses WarrantExpenses	1154905	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1490759	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	481282	usd
CY2021	qprc	Loss On Conversion Of Debt LossOnConversionOfDebt	-305556	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-730378	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1651614	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-413333	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-291702	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1077426	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1039454	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-754769	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4152993	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1253	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1806	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-753516	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4154799	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5332660	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5118638	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6841678	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1248000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	555556	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	598188	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	668010	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4154799	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7926723	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	117412	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-753516	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8562827	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-753516	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4154799	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	88094	usd
CY2022	qprc	Change In Fair Market Value Of Warrant Liabilitys ChangeInFairMarketValueOfWarrantLiabilitys	-1490759	usd
CY2021	qprc	Change In Fair Market Value Of Warrant Liabilitys ChangeInFairMarketValueOfWarrantLiabilitys	481282	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	117412	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1916011	usd
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	1154905	usd
CY2021	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1725965	usd
CY2021	qprc	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt	1850018	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	910326	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1159865	usd
CY2021	qprc	Loss On Conversions Of Debt LossOnConversionsOfDebt	305556	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	730378	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1651614	usd
CY2021	us-gaap	Other Nonrecurring Expense OtherNonrecurringExpense	667	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1032219	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	412602	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	203526	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6984	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6371	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	19108	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1036637	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-136335	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-914178	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49673	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1502000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1150000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1502000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1150000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-8500	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-1750000	usd
CY2021	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-9000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2303000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3900000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	52561	usd
CY2021	qprc	Payments To Acquire Purchase Price Of Patents PaymentsToAcquirePurchasePriceOfPatents	924349	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2241939	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1216651	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-174239	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16978	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	264840	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	247862	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90601	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	264840	usd
CY2021	qprc	Shares Issued For Conversion Of Debt SharesIssuedForConversionOfDebt	555556	usd
CY2022	qprc	Interest Added To Principal InterestAddedToPrincipal	4895	usd
CY2021	qprc	Interest Added To Principal InterestAddedToPrincipal	5626	usd
CY2021	qprc	Options Granted For Settlement Of Debt OptionsGrantedForSettlementOfDebt	598188	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1253	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1806	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1652000	usd
CY2022	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Patent Licensing Fees</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers”. Revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Under Topic 606, revenue is recognized when there is a contract which has commercial substance which is approved by both parties and identifies the rights of the parties and the payment terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company’s operating subsidiaries as part of the settlement of litigation commenced by the Company’s subsidiaries. Intellectual property rights granted included the following, as applicable: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The intellectual property rights granted were perpetual in nature, extending until the legal expiration date of the related patents. The individual intellectual property rights are not accounted for as separate performance obligations, as (a) the nature of the promise, within the context of the contract, is to transfer combined items to which the promised intellectual property rights are inputs and (b) the Company’s promise to transfer each individual intellectual property right described above to the customer is not separately identifiable from other promises to transfer intellectual property rights in the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the promised intellectual property rights are not individually distinct, the Company combined each individual IP right in the contract into a bundle of IP rights that is distinct, and accounted for all of the intellectual property rights promised in the contract as a single performance obligation. The intellectual property rights granted were “functional IP rights” that have significant standalone functionality. The Company’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. The Company’s subsidiaries have no further obligation with respect to the grant of intellectual property rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant (i.e., transfer of control) of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the intellectual property rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 30 to 90 days of execution of the contract. Contractual payments made by licensees are generally non-refundable. The Company does not have any significant payment terms, as payment is received shortly after goods are delivered or services are provided, therefore there is no significant financing component or consideration payable to the customer in these transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
CY2022	qprc	Number Of Customers NumberOfCustomers	1	pure
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.55	pure
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.82	pure
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced any such losses in these accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1150000	usd
CY2021Q3	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	1726000	usd
CY2022	qprc	Warrants Granted WarrantsGranted	962463	shares
CY2022	qprc	Purchase Agreement Stock Options PurchaseAgreementStockOptions	500000	shares
CY2022	qprc	Stock Options Granted To Officers And Consultants StockOptionsGrantedToOfficersAndConsultants	600000	usd
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	26189000	usd
CY2022	qprc	Negative Working Capital NegativeWorkingCapital	9490000	usd
CY2022Q4	us-gaap	Due To Other Related Parties Current And Noncurrent DueToOtherRelatedPartiesCurrentAndNoncurrent	138000	usd
CY2021Q4	us-gaap	Due To Other Related Parties Current And Noncurrent DueToOtherRelatedPartiesCurrentAndNoncurrent	138000	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	296000	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	282000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	750000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	962463	shares
CY2022Q4	us-gaap	Short Term Debt Percentage Bearing Variable Interest Rate ShortTermDebtPercentageBearingVariableInterestRate	0.10	pure
	qprc	Purchase Agreement PurchaseAgreement	92000	usd
CY2022Q3	qprc	Purchase Price Percentage PurchasePricePercentage	0.50	pure
CY2022Q3	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	350000	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	35000	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2796500	usd
CY2021Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2805000	usd
CY2015Q4	qprc	Purchase Agreement PurchaseAgreement	4672810	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	250000	usd
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	1750000	usd
CY2022	qprc	Loss On Debt Conversion LossOnDebtConversion	305556	usd
CY2022	qprc	Asset Acquired Description AssetAcquiredDescription	(v) Pursuant to the MPA-NA, until the TMPO has been paid in full, Intelligent Partners is entitled to receive 10% of the net proceeds realized from new assets acquired by the Company. If, in any calendar quarter, net proceeds realized exceed $1,000,000, Intelligent Partners’ entitlement for that quarter only shall increase to 30% on the portion of net proceeds in excess of $1,000,000 but less than $3,000,000. If in the same calendar quarter, net proceeds exceed $3,000,000, Intelligent Partners’ entitlement for that quarter only shall increase to 50% on the portion of net proceeds in excess of $3,000,000.
CY2022	qprc	Payments For Loan PaymentsForLoan	275000	usd
CY2022	qprc	Obligation Excess ObligationExcess	1000000	usd
CY2021	qprc	Loss On Extinguishment Note LossOnExtinguishmentNote	730378	usd
CY2022	qprc	Carrying Amount As Of The Restructure Date CarryingAmountAsOfTheRestructureDate	-4672810	usd
CY2022	qprc	Net Carrying Amount NetCarryingAmount	4672810	usd
CY2022	qprc	Cash Payment CashPayment	-1750000	usd
CY2022	qprc	Conversion Of Transferred Note ConversionOfTransferredNote	-250000	usd
CY2022	qprc	Fair Value Of Option Grant FairValueOfOptionGrant	-598188	usd
CY2022	qprc	Undiscounted Future Cash Flows UndiscountedFutureCashFlows	2805000	usd
CY2022	qprc	Loss On Extinguishment LossOnExtinguishment	-730378	usd
CY2020Q2	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2050-05-14
CY2020Q1	qprc	Deducted Loan Amount DeductedLoanAmount	100	usd
CY2020Q1	qprc	Loan Origination Cost loanOriginationCost	1000	usd
CY2022	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	$53,665
CY2021	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	$190,000
CY2022	qprc	Acquisition Funding AcquisitionFunding	95000	usd
CY2022	qprc	Funder Received FunderReceived	190000	usd
CY2022Q4	us-gaap	Obligation With Joint And Several Liability Arrangement Amount Outstanding ObligationWithJointAndSeveralLiabilityArrangementAmountOutstanding	136000	usd
CY2021Q1	us-gaap	Shares Issued SharesIssued	962463	shares
CY2021Q1	qprc	Warrant Yield Percentage WarrantYieldPercentage	0.10	pure
CY2021Q1	qprc	Aggregate Number Of Outstanding Shares AggregateNumberOfOutstandingShares	0.10	pure
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	145000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1636000	usd
CY2022	qprc	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	3.74	pure
CY2021	qprc	Fair Value Assumption Expected Volatility Rate FairValueAssumptionExpectedVolatilityRate	3.73	pure
CY2022	qprc	Fair Value Assumption Exercise Price FairValueAssumptionExercisePrice	0.0054	pure
CY2021	qprc	Fair Value Assumption Exercise Price FairValueAssumptionExercisePrice	0.0054	pure
CY2022	qprc	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0137	pure
CY2021	qprc	Fair Value Assumption Risk Free Interest Rate FairValueAssumptionRiskFreeInterestRate	0.0137	pure
CY2022	qprc	Fair Value Assumption Expected Term FairValueAssumptionExpectedTerm	P8Y1M6D
CY2021	qprc	Fair Value Assumption Expected Term FairValueAssumptionExpectedTerm	P9Y4M24D
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1154905	usd
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	481282	usd
CY2020Q4	qprc	Warrant Liability WarrantLiability	1636187	usd
CY2022	qprc	Gain On Subsequent Measurementin Dollars GainOnSubsequentMeasurementinDollars	-1490759	usd
CY2022Q4	qprc	Warrant Liability WarrantLiability	145428	usd
CY2021Q1	qprc	Purchase Value PurchaseValue	598000	usd
CY2021Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount Rates ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountRates	0.0137	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.52	pure
CY2021Q1	qprc	Shares Currently Owned SharesCurrentlyOwned	500000	shares
CY2021Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	462963	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	500000	shares
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	100000	shares
CY2022Q4	qprc	Total Shares Issued TotalSharesIssued	300000	shares
CY2022	qprc	Restricted Stock Description RestrictedStockDescription	The Company recorded professional fees in the amount of $240,000 as a result the restricted stock grants to these two consultants. The Company determined the fair value of the options as of the grant date to be approximately $720,000 using the Black-Scholes pricing model. Variables used in the valuation include (1) discount rate of 1.37%; (2) term of 10 years; (3) computed volatility of 252% and (4) zero expected dividends. The Company determined that the first performance condition was met and accrued the option expense of approximately $240,000 over the period from the grant date to achievement of the performance condition.
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	240000	usd
CY2021Q1	us-gaap	Restricted Cash Nature Of Restriction Description RestrictedCashNatureOfRestrictionDescription	the board of directors:(i) Granted restricted stock grants for services rendered and vesting in full upon grant, to: a.Jon C. Scahill – 490,000 shares b.Timothy J. Scahill – 100,000 shares c.Dr. William R. Carroll - 100,000 shares (ii) Granted Jon Scahill a ten-year option (the “Option”) to purchase 600,000 shares of Common Stock which become exercisable cumulatively as follows: a.200,000 shares at an exercise price of $1.00 per share becoming exercisable upon the commencement of trading of the Common Stock on the OTCQB. b.200,000 shares at an exercise price of $3.00 per share, becoming exercisable on the first day on which the Company files with the SEC a Form 10-K or Form 10-Q which reports stockholders’ equity of at least $5,000,000, and c.200,000 shares at an exercise price of $5.00 per share becoming exercisable on the date on which the Common Stock is listed for trading on the Nasdaq Stock Market or the New York Stock Exchange (iii) Appointed Ryan T. Logue to the board of directors and granted Mr. Logue a restricted stock grant of 500,000 shares of common stock which vested upon his acceptance of his appointment as a director. The Company recognized compensation expense of $888,000 in conjunction with issuance of common stock to officers and directors during the year ended December 31, 2021. The Company determined the fair value of the options to be approximately $720,000 as of the grant date using the Black-Scholes pricing model. Variables used in the valuation include (1) discount rate of 1.37%; (2) term of 10 years; (3) computed volatility of 252% and (4) zero expected dividends.
CY2021	qprc	Stock Option Expense StockOptionExpense	240000	usd
CY2021	qprc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P8Y7M24D
CY2021	qprc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P7Y9M18D
CY2022	qprc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P6Y9M18D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	930000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1116456	usd
CY2022	qprc	Patent Patent	2757000	usd
CY2021	qprc	Patent Patent	5617117	usd
CY2021	us-gaap	Asset Retirement Obligation Period Increase Decrease AssetRetirementObligationPeriodIncreaseDecrease	-4362117	usd
CY2022Q4	qprc	Finite Lived Intangible Assets Total FiniteLivedIntangibleAssetsTotal	2757000	usd
CY2021Q4	qprc	Finite Lived Intangible Assets Total FiniteLivedIntangibleAssetsTotal	1255000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1625846	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	715519	usd
CY2022Q4	qprc	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	1131154	usd
CY2021Q4	qprc	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	539481	usd
CY2022	qprc	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y5M23D
CY2021	qprc	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P11Y7D
CY2022	us-gaap	Impaired Intangible Asset Description ImpairedIntangibleAssetDescription	●patents acquired in October 2015 for a purchase price of $3,000,000, the useful lives of the patents, at the date of purchase, was 6-10 years; these patents were disposed of as of December 31, 2021 ●patents acquired in July 2017 pursuant to an obligation to pay 50% of net revenues to IV 34/37 (see Note 3); the useful lives of the patents, at the date of acquisition, was 5-6 years; these patents were disposed of as of December 31, 2021. ●patents (which were fully amortized at the date of acquisition) acquired in January 2018 pursuant to an agreement with to Intellectual Ventures Assets 62 LLC and Intellectual Ventures Assets 71 LLC “(IV 62/71”), pursuant to which CXT has an obligation to distribute 50% of net revenues to IV 62/71; ●patents (which were fully amortized at the date of acquisition) acquired in January 2018 by Photonic Imaging Solutions Inc. (“PIS”) from Intellectual Ventures Assets 64 LLC (“IV 64”) pursuant to which PIS is to pay IV 64 (a) 70% of the first $1,500,000 of net revenue, (b) 30% of the next $1,500,000 of net revenue and (c) 50% of net revenue in excess of $3,000,000; ●patents acquired in March 2019 pursuant to an obligation to pay 50% of net revenues to IV 113/108 (see Note 3); the useful lives of the patents, at the date of acquisition, was approximately 9 years, these patents were disposed of as of December 31, 2021. ●patents (which were fully amortized at the date of acquisition) acquired in May 2020 for a purchase price of $95,000 pursuant to an agreement with Texas Technology Ventures 2, LLP (“TTV”), pursuant to which of the Company retains the first $230,000 of net proceeds, as defined in the agreement, after which the company has an obligation to distribute 50% of net proceeds to TTV. ●patents (which were fully amortized at the date of acquisition) acquired in February 2021 pursuant to an agreement with PKT for a purchase price of $350,000, pursuant to which $350,000 was paid at closing, and upon the realization of gross proceeds, as defined in the agreement, the Company shall make a subsequent or payments in the aggregate amount of $93,900, representing reimbursement to PKT, as the prosecuting attorney, for legal fees associated with prosecution of the portfolio, such reimbursement shall be due and payable to PKT from time to time as gross proceeds are realized, if any, and paid to PKT along with and in proportion to reimbursement to other third parties of costs incurred in realizing gross proceeds. Thereafter, PKT is entitled to a percentage of gross proceeds realized, if any. ●patents (which were fully depreciated at the date of acquisition) acquired in May 2021 for a purchase price of $250,000. ●patents acquired in October 2021 from AI for a purchase price of $550,000 pursuant to which the Company retains an amount equal to the purchase price plus any fees incurred out of net proceeds, as defined in the agreement, after which AI is entitled to a percentage of further net proceeds realized, if any; the useful lives of the patents, at the date of acquisition, was approximately 11 years. ●patents acquired in January 2022 for a purchase price of $1,060,000, the useful lives of the patents, at the date of purchase, was approximately 1-2 years. ●patents acquired in July 2022 via assignment from AI for a purchase price of $92,000, the useful lives of the patents, at the date of purchase, was approximately 2-4 years. ●patents acquired July 2022 pursuant to an agreement with Hewlett Packard Enterprise Development LP and Hewlett Packard Enterprise Company for a purchase price of $350,000. The useful lives of the patents, at the date of purchase, was approximately 2-9 years.
CY2021Q4	qprc	Purchase Price PurchasePrice	550000	usd
CY2021Q4	qprc	Useful Livers Acquisition UsefulLiversAcquisition	P11Y
CY2022	us-gaap	Impaired Intangible Asset Facts And Circumstances Leading To Impairment ImpairedIntangibleAssetFactsAndCircumstancesLeadingToImpairment	For the year ended December 31, 2021, the Company recorded non-cash impairment charges of approximately $1,652,000 to write down finite lived intangible assets in the Power Management/Bus Controller, CXT and M-RED portfolios.
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	910000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1159865	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	457894	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	218352	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	123730	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	83205	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	47927	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	200046	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1131154	usd
CY2022	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2021	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2022	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2021	qprc	Noncontrolling Interest NoncontrollingInterest	228	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	11635198	usd
CY2022	us-gaap	Valuation Allowance Commentary ValuationAllowanceCommentary	$77,946
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2713220	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2591027	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	162465	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	206712	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2875685	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2797739	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1253	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1806	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1253	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1806	usd
CY2022	qprc	Book Income Before Taxes Tax BookIncomeBeforeTaxesTax	-158501	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	560	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	-0.0007	pure
CY2022	qprc	Warrant Income Tax WarrantIncomeTax	-313059	usd
CY2022	qprc	Warrant Income Percentage WarrantIncomePercentage	0.4148	pure
CY2022	us-gaap	Interest Expense InterestExpense	82720	usd
CY2022	qprc	Interest Expense Percentage InterestExpensePercentage	-0.1096	pure
CY2022	qprc	Change In Tax Rate Tax ChangeInTaxRateTax	39752	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0527	pure
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	77946	usd
CY2022	qprc	Change In Valuation Allowance Percentage ChangeInValuationAllowancePercentage	-0.1033	pure
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	269329	usd
CY2022	qprc	Change In Estimate For Prior Year Taxes Percentage ChangeInEstimateForPriorYearTaxesPercentage	-0.3568	pure
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1253	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0017	pure
CY2021	qprc	Book Income Before Taxes Tax BookIncomeBeforeTaxesTax	-872129	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1427	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0003	pure
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Government Grants IncomeTaxExpenseBenefitContinuingOperationsGovernmentGrants	-4375	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.0011	pure
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	873	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	-0.0002	pure
CY2021	qprc	Warrant Expense Tax WarrantExpenseTax	242530	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies Other EffectiveIncomeTaxRateReconciliationTaxContingenciesOther	-0.0584	pure
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	402362	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0969	pure
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	64167	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	-0.0155	pure
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	75059	usd
CY2021	qprc	Change In Valuation Allowance Percentage ChangeInValuationAllowancePercentage	-0.0181	pure
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	101069	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0243	pure
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9177	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0022	pure
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1806	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0004	pure
CY2021	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.10	pure
CY2022Q4	qprc	Compensation Percentage CompensationPercentage	0.20	pure
CY2021Q4	qprc	Compensation Percentage CompensationPercentage	0.19	pure
CY2021Q3	qprc	Net Proceeds Percentage NetProceedsPercentage	0.50	pure
CY2022	us-gaap	Legal Fees LegalFees	500	usd
CY2022	qprc	Total Consideration TotalConsideration	0	usd
CY2022	qprc	Operating Expense OperatingExpense	4000000	usd
CY2022	qprc	Cash Payment Funds CashPaymentFunds	3300000	usd
CY2022	qprc	Acquisitions Intends AcquisitionsIntends	25000000	usd
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022	us-gaap	Other Income OtherIncome		usd
CY2022	qprc	Warrant Expenses WarrantExpenses		usd
CY2022	qprc	Loss On Conversion Of Debt LossOnConversionOfDebt		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2022	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices		usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2022	qprc	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt		usd
CY2022	qprc	Loss On Conversions Of Debt LossOnConversionsOfDebt		usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2022	us-gaap	Other Nonrecurring Expense OtherNonrecurringExpense		usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
CY2022	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt		usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	qprc	Payments To Acquire Purchase Price Of Patents PaymentsToAcquirePurchasePriceOfPatents		usd
CY2022	qprc	Shares Issued For Conversion Of Debt SharesIssuedForConversionOfDebt		usd
CY2022	qprc	Options Granted For Settlement Of Debt OptionsGrantedForSettlementOfDebt		usd
CY2022	qprc	Less Unamortized Debt Discount And Issuance Costs LessUnamortizedDebtDiscountAndIssuanceCosts		usd
CY2022	qprc	Reacquisition Price ReacquisitionPrice		usd
CY2022	qprc	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate		pure
CY2021	qprc	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate		pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2021	qprc	Exercised Weighted Average Remaining Contractual Term ExercisedWeightedAverageRemainingContractualTerm
CY2021	qprc	Expired Weighted Average Remaining Contractual Term ExpiredWeightedAverageRemainingContractualTerm
CY2021	qprc	Cancelled Weighted Average Remaining Contractual Term CancelledWeightedAverageRemainingContractualTerm
CY2022	qprc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
CY2022	qprc	Exercised Weighted Average Remaining Contractual Term ExercisedWeightedAverageRemainingContractualTerm
CY2022	qprc	Expired Weighted Average Remaining Contractual Term ExpiredWeightedAverageRemainingContractualTerm
CY2022	qprc	Cancelled Weighted Average Remaining Contractual Term CancelledWeightedAverageRemainingContractualTerm
CY2022	us-gaap	Asset Retirement Obligation Period Increase Decrease AssetRetirementObligationPeriodIncreaseDecrease		usd
CY2022Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity		usd
CY2021Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes		pure
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000824416

Files In Submission

Name	View Source	Status
0001213900-23-025520-index-headers.html	Edgar Link	pending
0001213900-23-025520-index.html	Edgar Link	pending
0001213900-23-025520.txt	Edgar Link	pending
0001213900-23-025520-xbrl.zip	Edgar Link	pending
f10k2022ex10-8_questpatent.htm	Edgar Link	pending
f10k2022ex31-1_questpatent.htm	Edgar Link	pending
f10k2022ex32-1_questpatent.htm	Edgar Link	pending
f10k2022_questpatent.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qprc-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
qprc-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
qprc-20221231_def.xml	Edgar Link	unprocessable
qprc-20221231_lab.xml	Edgar Link	unprocessable
qprc-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_questpatent_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc

2023 Q1 Form 10-K Financial Statement

#000121390023025520 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QPRC QUEST PATENT RESEARCH CORP Stock $qprc

2023 Q1 Form 10-K Financial Statement

#000121390023025520 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc